Devonian Health【GSD】銘柄情報

Devonian Health Group Inc (GSD) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

7.50

( -6.37% )

買値

7.50

売値

11.12

出来高

240

7.50 日の範囲 7.50

0.085 52 週間の範囲 14.99

時価総額

20.856M

前日終値

8.01

始値

7.50

時刻

200

7.5

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 1,044

発行済株式数

2,780,866

配当利回り

PER

-3.6

1 株当たり利益 (EPS)

-2.26

歳入

純利益

-6.11M

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinic... Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

groupedevonian.com

本社

Québec, Canada

設立

Devonian Health Group Inc is listed in the Healthcare sector of the トロントベンチャー取引所 with ticker GSD. The last closing price for Devonian Health was $8.01. Over the last year, Devonian Health shares have traded in a share price range of $ 0.085 to $ 14.99.

Devonian Health currently has 2,780,866 shares in issue. The market capitalisation of Devonian Health is $20.86 million. Devonian Health has a price to earnings ratio (PE ratio) of -3.60.

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30...

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Devonian Reports Results of its Annual General and Special Meeting of Shareholders Canada NewsWire QUÉBEC...

Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026

Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January...

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.75	-18.9189189189	9.25	9.25	7.5	1683	8.13106373	CS
4	-3.65	-32.735426009	11.15	11.15	7.5	565	8.89792795	CS
12	-4.5	-37.5	12	12	7.5	243	9.4102035	CS
26	7.325	4185.71428571	0.175	14.99	0.17	2965	1.75304488	CS
52	7.365	5455.55555556	0.135	14.99	0.085	7734	0.47588632	CS
156	7.25	2900	0.25	14.99	0.075	7827	0.27083861	CS
260	7.11	1823.07692308	0.39	14.99	0.075	6755	0.32725563	CS